OverviewSuggest Edit

Novartis is a company that researches, develops, manufactures, and markets a range of healthcare products. It comprises 2 global operation divisions: Innovative Medicines and Sandoz. The Innovative Medicines division offers patented prescription medicines, commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz division provides active ingredients and finished dosage forms of pharmaceuticals in the areas of the cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, and respiratory. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as contact lenses and contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers.
TypePublic
Founded1996
HQBasel, CH
Websitenovartis.com
Employee Ratings3.9

Latest Updates

Employees (est.) (Dec 2019)103,914(-16%)
Job Openings1,225
Revenue (FY, 2017)$49.1 B(+2%)
Share Price (Jul 2020)CHF83.5
Cybersecurity ratingAMore

Key People/Management at Novartis

Vasant Narasimhan

Vasant Narasimhan

Chief Executive Officer
Joerg Reinhardt

Joerg Reinhardt

Chairman
Steven Baert

Steven Baert

Chief People & Organization Officer
Enrico Vanni

Enrico Vanni

Vice Chairman
Ameet Mallik

Ameet Mallik

Executive Vice President, Novartis Oncology US
Bertrand Bodson

Bertrand Bodson

Chief Digital Officer
Show more

Novartis Office Locations

Novartis has offices in Basel, Schweizerhalle, Stein, Broomfield and in 167 other locations
Basel, CH (HQ)
Fabrikstrasse 2
Basel, CH
210, Lichtstrasse 35
Basel, CH
Fabrikstrasse 18
Basel, CH
Klybeckstrasse 141
Schweizerhalle, CH
Rothausstrasse 61
Stein, CH
Schaffhauserstrasse
Show all (185)

Novartis Financials and Metrics

Novartis Revenue

Embed Graph
View revenue for all periods
Novartis's revenue was reported to be $49.11 b in FY, 2017 which is a 1.2% increase from the previous period.
USD

Revenue (FY, 2017)

49.1b

Revenue growth (FY, 2016 - FY, 2017), %

1.2%

Gross profit (FY, 2017)

31.9b

Gross profit margin (FY, 2017), %

65%

Net income (FY, 2017)

7.7b

Market capitalization (6-Jul-2020)

191.0b

Closing stock price (6-Jul-2020)

83.5

Cash (31-Dec-2017)

8.9b
Novartis's current market capitalization is CHF191 b.
USDFY, 2015FY, 2016FY, 2017

Revenue

49.4b48.5b49.1b

Revenue growth, %

(8%)(2%)1%

Cost of goods sold

17.4b17.5b17.2b

Gross profit

32.0b31.0b31.9b
USDFY, 2016FY, 2017

Cash

7.0b8.9b

Accounts Receivable

8.2b8.6b

Inventories

6.3b6.9b

Current Assets

24.9b28.2b
USDFY, 2015FY, 2016FY, 2017

Net Income

7.0b6.7b7.7b

Cash From Operating Activities

11.9b11.5b12.6b

Purchases of PP&E

(2.4b)(1.9b)(1.7b)

Cash From Investing Activities

(10.8b)(3.4b)(3.1b)
Show all financial metrics

Novartis Operating Metrics

FY, 2015FY, 2016FY, 2017

Major Approvals (US, EU, JP)

20 16 16

Major Submissions (US, EU, JP)

14 24 16

Patients Reached

972 m965 m927 m

Projects Entering Development Pipeline

8 5 9
Show all operating metrics

Novartis Acquisitions / Subsidiaries

Company NameDateDeal Size
AmblyotechApril 21, 2020
The Medicines CompanyNovember 25, 2019$9.70 b
EndocyteOctober 18, 2018
Advanced Accelerator ApplicationsOctober 30, 2017$3.90 b
AveXis$8.70 b

Novartis Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Novartis Revenue Breakdown

Embed Graph

Novartis revenue breakdown by business segment: 67.2% from Innovative Medicines, 20.5% from Sandoz and 12.3% from Alcon

Novartis revenue breakdown by geographic segment: 34.5% from United States, 7.5% from Germany, 5.1% from France, 6.5% from Japan and 46.5% from Other

Novartis Online and Social Media Presence

Embed Graph

Novartis News and Updates

Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU

Basel, July 7, 2020 — Novartis today announced that the European Commission (EC) has approved Enerzair® Breezhaler® (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) as a maintenance treatment of asthma in adult patients not adequately controlled with a mainte…

Global Contact Lens Market Study 2020-2025 Featuring Profiles of Major Players Essilor Int'l, Novartis, Bausch Health Companies, Zeiss Group, and the Cooper Companies Amongst Others

DUBLIN, July 6, 2020 /PRNewswire/ -- The "Contact Lens Market- Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The global contact lens market is projected to register a CAGR of 5.92% during the forecast period, 2020 to 2025. In order...

AccessNow wins $250,000 USD Novartis Prize for its accessibility platform

Toronto-based AccessNow recently won the Novartis Prize for Assistive Tech for Multiple Sclerosis (MS) beating over 150 submissions. AccessNow plans to use the funding...

Novartis Pharmaceuticals Agrees To Pay $678 Million To Settle Shepherd, Finkelman, Miller & Shah, LLP False Claims Act Qui Tam Case

NEW YORK, July 1, 2020 /PRNewswire/ -- James E. Miller of Shepherd, Finkelman, Miller & Shah, LLP ("SFMS")(www.sfmslaw.com), Lead Counsel for Plaintiff-Relator, Oswald Bilotta (the "Relator" or "Whistleblower"), announced today that Novartis Pharmaceuticals Corporation ("Novartis") has...

Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US and positioning company for the future by fully scaling its next-generation digital engagement technologies

Basel, July 2, 2020 – Novartis has finalized its previously disclosed agreement with the US Attorney’s Office for the Southern District of New York, the New York State Attorney General, and relator Oswald Bilotta resolving a civil suit challenging speaker programs and other promotional events conduc…

The CEO of Novartis on Developing Drugs During a Pandemic

Vas Narasimhan talks about drug prices, vaccine development, the rise and fall of hydroxychloroquine, and how Big Pharma might win back the trust of consumers.
Show more

Novartis Frequently Asked Questions

  • When was Novartis founded?

    Novartis was founded in 1996.

  • Who are Novartis key executives?

    Novartis's key executives are Vasant Narasimhan, Joerg Reinhardt and Steven Baert.

  • How many employees does Novartis have?

    Novartis has 103,914 employees.

  • What is Novartis revenue?

    Latest Novartis annual revenue is $49.1 b.

  • What is Novartis revenue per employee?

    Latest Novartis revenue per employee is $472.6 k.

  • Who are Novartis competitors?

    Competitors of Novartis include Bayer, Pfizer and Johnson & Johnson.

  • Where is Novartis headquarters?

    Novartis headquarters is located at Fabrikstrasse 2, Basel.

  • Where are Novartis offices?

    Novartis has offices in Basel, Schweizerhalle, Stein, Broomfield and in 167 other locations.

  • How many offices does Novartis have?

    Novartis has 185 offices.